{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:04:35Z","timestamp":1785409475615,"version":"3.56.0"},"reference-count":23,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China Foundation for Hepatitis Prevention and Control","award":["YGFK20210077"],"award-info":[{"award-number":["YGFK20210077"]}]},{"name":"China Foundation for Hepatitis Prevention and Control","award":["YGFK20170058"],"award-info":[{"award-number":["YGFK20170058"]}]},{"award":["YGFK20210077"],"award-info":[{"award-number":["YGFK20210077"]}],"id":[{"id":"https:\/\/ror.org\/05t7bek56","id-type":"ROR","asserted-by":"publisher"}]},{"award":["YGFK20170058"],"award-info":[{"award-number":["YGFK20170058"]}],"id":[{"id":"https:\/\/ror.org\/05t7bek56","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Health Commission of Fujian Province","award":["2020GGB020"],"award-info":[{"award-number":["2020GGB020"]}]},{"award":["2020GGB020"],"award-info":[{"award-number":["2020GGB020"]}],"id":[{"id":"https:\/\/ror.org\/0136mc929","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004476","name":"Chinese Center For Disease Control and Prevention","doi-asserted-by":"publisher","award":["Entrusted Business Task Agreement"],"award-info":[{"award-number":["Entrusted Business Task Agreement"]}],"id":[{"id":"10.13039\/501100004476","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Entrusted Business Task Agreement"],"award-info":[{"award-number":["Entrusted Business Task Agreement"]}],"id":[{"id":"https:\/\/ror.org\/04wktzw65","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Objective: This study evaluated hepatitis B vaccine (HepB) uptake, associated influencing factors, and post-vaccination immune responses among preterm infants residing in Fujian Province. The findings can support targeted improvements in hepatitis B prevention and control strategies tailored for this high-risk neonatal population. Methods: We conducted a multicenter cross-sectional study combined with short-term prospective serological follow-up across five counties, cities and districts of Fujian Province between 2022 and 2023. A total of 779 eligible preterm infants were enrolled in this study. We collected demographic information of participating mothers and infants, as well as complete HepB vaccination records throughout the study period. For 363 enrolled infants, we performed serological tests to detect hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (HBsAb) at 1\u20132 months after they completed the full HepB vaccination series. To explore factors linked to timely administration of the first HepB dose (HepB1), completion of the full vaccination course and HBsAb serostatus, we adopted a set of statistical approaches including descriptive statistics, the chi-square test (Fisher\u2019s exact test was used for groups with small sample sizes) and binary logistic regression. Results: The timely HepB1 vaccination rate among all preterm infants was 78.18%, while 63.80% completed the full vaccination schedule as required. In the serology cohort, the HBsAb positive rate was 90.91%, and 8.82% of infants showed double-negative HBsAg and HBsAb results, indicating susceptibility to HBV infection. Multivariate analysis identified multiple risk factors for delayed vaccination. Preterm infants were more likely to receive vaccinations late if their mothers tested HBsAg-negative (HepB1: OR = 25.231, 95%CI: 4.997\u2013127.406; full-course HepB: OR = 2.440, 95%CI: 1.395\u20134.269), were delivered in county-level or lower-tier medical facilities (HepB1: OR = 3.724, 95%CI: 2.107\u20136.580), or were born via cesarean section (HepB1: OR = 3.460, 95%CI: 2.169\u20135.520; full-course HepB: OR = 1.954, 95%CI: 1.411\u20132.704). Additional risk factors included a gestational age below 34 weeks (HepB1: OR = 4.369, 95%CI: 1.894\u201310.081; full-course HepB: OR = 2.237, 95%CI: 1.148\u20134.359) and a birth weight less than 2500 g (HepB1: OR = 2.251, 95%CI: 1.397\u20133.629; full-course HepB: OR = 1.513, 95%CI: 1.065\u20132.150). Conclusions: Preterm infants enrolled from five regions in Fujian Province achieved robust immune protection following standard HepB vaccination. However, timely first-dose coverage and on-schedule full-course vaccination remain suboptimal in this cohort. Observed gaps in routine vaccination management at primary care settings highlight a key area for improvement in local hepatitis B prevention. Targeted standardized training for maternity care staff at county-level facilities, paired with a full-cycle follow-up system for preterm infant vaccination, may further strengthen hepatitis B mother-to-child transmission (MTCT) interruption in the study regions.<\/jats:p>","DOI":"10.3390\/vaccines14070583","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:50:37Z","timestamp":1782867037000},"page":"583","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunization Status and Effectiveness Analysis of Hepatitis B Vaccine Among Preterm Infants in Fujian Province, 2022\u20132023"],"prefix":"10.3390","volume":"14","author":[{"given":"Hairong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Immunization Program, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, China"},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research, Fuzhou 350012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5362-3707","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, China"},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research, Fuzhou 350012, China"},{"name":"Department of Preventive Medicine, School of Public Health, Xiamen University, Xiamen 361102, China"},{"name":"Naqu Prefecture Center for Disease Control and Prevention, Naqu 852000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikun","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, China"},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research, Fuzhou 350012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, China"},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research, Fuzhou 350012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2641857","DOI":"10.1080\/21645515.2026.2641857","article-title":"Global, regional, and national burden of chronic hepatitis B, 1990\u20132021, and projections to 2030: An urgent call for action to achieve hepatitis B elimination goals by 2030","volume":"22","author":"Shen","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","first-page":"486","article-title":"Incidence and mortality trends of hepatitis B virus-related liver cancer in China from 1990 to 2019","volume":"31","author":"Jia","year":"2024","journal-title":"Chin. J. Cancer Prev. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","article-title":"Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: A systematic literature review and meta-analysis of 3740 studies and 231 million people","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"ref_4","first-page":"1","article-title":"Investigation and analysis on sero-epidemiology of hepatitis B in Fujian, China, 2019\u20132020","volume":"27","author":"Yang","year":"2021","journal-title":"Strait. J. Prev. Med."},{"key":"ref_5","first-page":"101193","article-title":"New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020","volume":"51","author":"Zheng","year":"2024","journal-title":"Lancet Reg. Health West Pac."},{"key":"ref_6","first-page":"8","article-title":"Analysis of maternal hepatitis B infection in Quanzhou, Fujian Province, 2015\u22122022","volume":"14","author":"Lin","year":"2023","journal-title":"Chin. J. Women Child Health"},{"key":"ref_7","first-page":"1045","article-title":"Vaccination strategies of premature infants and low birth weight infants","volume":"32","author":"Zhang","year":"2017","journal-title":"Chin. J. Appl. Clin. Pediatr."},{"key":"ref_8","unstructured":"Infectious Diseases Physicians Branch, Chinese Medical Doctor Association, and Chinese Society of Infectious Diseases, Chinese Medical Association (2024). Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus (version 2024). J. Clin. Hepatol., 40, 1557\u20131566."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Goedicke-Fritz, S., H\u00e4rtel, C., Krasteva-Christ, G., Kopp, M.V., Meyer, S., and Zemlin, M. (2017). Preterm birth affects the risk of developing immune-mediated diseases. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01266"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.arcped.2014.06.020","article-title":"Is the new vaccination schedule recommended in France adapted to premature babies?","volume":"21","author":"Gaudelus","year":"2014","journal-title":"Arch. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Huang, L.F., Huang, A.D., Zhang, X., Tang, L., An, J., Li, J., Zheng, H., Yin, Z.D., and Wang, F.Z. (2024). Immunization status and factors influencing hepatitis B vaccination of preterm infants in three provinces of China, 2019 to 2021. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09846-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2443423","DOI":"10.1001\/jamanetworkopen.2024.43423","article-title":"Regional disparities, economic development, and neonatal mortality and hospital delivery in China","volume":"7","author":"Fang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_13","first-page":"210","article-title":"Strategies and advances in hepatitis B vaccination in China","volume":"41","author":"Tang","year":"2025","journal-title":"J. Clin. Hepatol."},{"key":"ref_14","unstructured":"Xie, X., Kong, B.H., and Duan, T. (2018). Obstetrics and Gynecology, People\u2019s Medical Publishing House."},{"key":"ref_15","first-page":"1336","article-title":"Review on appropriate feeding for premature\/low birth weight infants","volume":"26","author":"Huo","year":"2018","journal-title":"Chin. J. Child Health Care"},{"key":"ref_16","unstructured":"(2021). Immunization schedules instructions for vaccines of the national immunization program (2021 version). Chin. J. Viral Dis., 11, 241\u2013245."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, X.Z., Gong, C.X., Du, X.L., Yang, Y.F., Kui, L.Y., Wang, L., Hao, T.T., Hou, Y., Wang, F., and Fan, N. (2025). Predictive model for neonatal HBV infection risk in infants of HBV-infected mothers in China: An observational study. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1536904"},{"key":"ref_18","unstructured":"Chinese Preventive Medicine Association (2021). Expert consensus on informed consent for vaccination (Part one). Pract. Prev. Med., 28, 385\u2013411."},{"key":"ref_19","unstructured":"National Health Commission of the People\u2019s Republic of China (2023). Action Plan for Eliminating Mother-to-Child Transmission of HIV, Syphilis, and Hepatitis B (2022\u20132025). Chin. J. Viral Dis., 13, 107\u2013160."},{"key":"ref_20","first-page":"883","article-title":"Study on premature infants immune response and adverse reaction to hepatitis B, polio, and measles vaccination","volume":"23","author":"Liu","year":"2015","journal-title":"Chin. J. Child Health Care"},{"key":"ref_21","unstructured":"Qin, W. (2023). Effectiveness of HepB Immunization and Cost-Effectiveness Analysis of HepB Booster Vaccination in Preterm Birth Children, Anhui Medical University."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kaiser, E., Weber, R., Bous, M., Fortmann, I., Dammann, M.-T., Mari\u00dfen, J., Viemann, D., Derouet, C., Hein, S., and Nourkami-Tutdibi, N. (2025). Insufficient immune protection in preterm infants due to delayed or incomplete hexavalent vaccination. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1626057"},{"key":"ref_23","first-page":"261","article-title":"Vaccination timeliness in preterm infants: A review of literature","volume":"19","author":"Zhou","year":"2023","journal-title":"Chin. J. Obstet. Gynecol. Pediatr. (Electron. Ed.)"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/583\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:15:26Z","timestamp":1783484126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070583"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070583","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}